Previous 10 | Next 10 |
Catalyst Pharmaceuticals (CPRX) comments on the recent decision by Health Canada to re-issue a Notice of Compliance ("NOC") for the company's rival drug Ruzurgi (amifampridine tablets), which is indicated to treat patients with Lambert-Eaton Myasthenic Syndrome ((LEMS)).The drug's o...
CORAL GABLES, Fla., June 28, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare ...
Shares of Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) traded at a new 52-week high today of $6.17. This new high was reached on below average trading volume as 301,000 shares traded hands, while the average 30-day volume is approximately 1.4 million shares. Catalyst Pharmaceuticals Inc. ...
Catalyst Pharmaceuticals (CPRX) has entered into an exclusive license and supply agreement with DyDo Pharma for the development and commercialization of Firdapse (amifampridine) Tablets 10 mg in Japan for the treatment of Lambert-Eaton myasthenic syndrome ((LEMS)).LEMS is a rare autoimmune ne...
CORAL GABLES, Fla., June 28, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare ...
- Without an NOC, Ruzurgi ® is without a Marketing Authorization in Canada - Matter Remanded Back to Health Canada to Provide a More Transparent Record of Its Decision in Light of Firdapse ® ’s Data Protection CORAL GABLES, Fla., June 03,...
Catalyst has registered solid performance over the past quarter and previous two years. Aside from its BioMarin deals, Catalyst's efforts to expand its pipeline have met with little success. Catalyst's pricing for Firdapse has generated controversy and competition. Catalyst is...
Catalyst Pharmaceuticals is a small cap biopharma company with a highly profitable ultra-orphan drug, Firdapse, for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS). Firdapse was the subject of a pricing controversy. Subsequently, FDA granted off-label approval ...
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) traded at a new 52-week high today of $5.69. This new high was reached on below average trading volume as 109,000 shares traded hands, while the average 30-day volume is approximately 1.3 million shares. In the past 52 weeks, Catalyst Pharmaceu...
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) traded at a new 52-week high today of $5.81. Approximately 109,000 shares have changed hands today, as compared to an average 30-day volume of 1.3 million shares. Catalyst Pharmaceuticals Inc. share prices have moved between a 52-week high of $...
News, Short Squeeze, Breakout and More Instantly...
Catalyst Pharmaceuticals Inc. Company Name:
CPRX Stock Symbol:
NASDAQ Market:
Catalyst Pharmaceuticals Inc. Website:
CORAL GABLES, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-...
CORAL GABLES, Fla., July 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-...
2024-06-20 17:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...